Description
TB-500 Refill 10mg is a Core Research catalogue product with 10mg TB-500 (nominal; exact molecular species requires specification) supplied in a sealed refill-cartridge presentation with lyophilised research material. This page describes the exact listing, its relation to alternative formats, the experimental literature on the named material and what batch or finished-format documentation can establish. It is supplied for laboratory research only, not for human or veterinary use.
What is actually supplied?
| Attribute | This product |
|---|---|
| Catalogue name | TB-500 Refill 10mg |
| Named material | TB-500 (exact molecular species requires specification) |
| Labelled amount | 10mg TB-500 (nominal; exact molecular species requires specification) |
| Presentation | Sealed refill-cartridge presentation with lyophilised research material |
| Purchase price and availability | Current live WooCommerce purchase panel |
| Documentation route | TB-500 Refill 10mg — batch-documentation enquiry |
The supplier title TB-500 is not a complete molecular specification. Literature uses that name for different thymosin-beta-4-related materials, so the sequence/terminal form and counter-ion should be established from the current product record before any precise molecular assignment.
This is the separately listed refill cartridge, not a standard vial or an automatically included reusable pen housing. Its hardware compatibility and any required accessories need confirmation against the particular dispensing system and the item being purchased.
Which presentation is the right catalogue item?
A refill changes the supplied container/format; it does not automatically show that the refill has the same chemical form, stability, analytical coverage or compatibility as a vial or a pen-format listing.
| Related product | What is different? |
|---|---|
| TB-500 10mg vial | Standalone lyophilised vial |
| TB-500 10mg Pen | Separate preloaded pen-format listing |
| BPC-157 / TB-500 Blend 10mg | Two-component vial, not TB-500 alone |
The distinction is practical rather than a claimed difference in biological activity. Compare the exact material, labelled amount, supplied container and documented finished format. The vial-versus-pen format guide explains why a common compound name does not establish matching formulation or hardware compatibility.
Why researchers investigate TB-500 and thymosin-beta-4-related materials
The studies here explain what was measured in specific preparations and experimental systems. They are compound-level evidence, not quality-control testing or performance trials for the supplied refill cartridge. For the detailed research discussion, see the TB-500 10mg vial research dossier.
What does the name TB-500 identify?
Esposito and colleagues characterised an N-terminally acetylated seven-residue fragment (Ac-LKKTETQ) in one preparation marketed as TB-500. That analytical finding identifies the sample they studied. Other papers investigate full-length thymosin beta-4, the unacetylated LKKTETQ sequence, or modified fragments. Their names cannot be used interchangeably to certify the identity of this catalogue item. 1
The actin-binding region is only part of the parent peptide
Mutational research on thymosin beta-4 mapped contributions to actin binding across the molecule. A short fragment sharing a region of the sequence need not reproduce every property of the full-length parent. That is especially important when extrapolating molecular findings to an unverified TB-500-labelled cartridge or filled pen. 2
Results differ by model and material
Philp and colleagues explored thymosin beta-4 and an actin-domain fragment in impaired dermal-wound animal models, including aged mice. Those tests concern the specific forms and injury models used, not every TB-500 preparation. 3
Shah and colleagues investigated an actin-related region in stimulated human hepatic stellate cells and reported reduced activation-associated measurements, proliferation and migration. A decrease in migration in that assay is not contradictory evidence to discard: it shows why effects cannot be described as universally promoting cell movement. 4
More recent TB-500/metabolite analysis found that the metabolite Ac-LKKTE, rather than the parent peptide, was the only tested material with a significant wound-healing screening response versus control in that particular fibroblast assay. Parent, fragment and metabolite outcomes must remain distinct. 5
How to check evidence for this exact refill
The most useful document identifies the tested sample, actual product, relevant format and lot. Ask whether a document covers source peptide, a filled cartridge, a two-component preparation (where relevant), or the item that would actually be dispatched. Each scope can answer different questions.
Before treating TB-500 scientific references as applicable, ask for the actual sequence, acetylation/terminal form and counter-ion, where available. An analytical result for one fragment, full-length thymosin beta-4 or a metabolite is not a surrogate test for another.
| What you need to know | Relevant evidence or question |
|---|---|
| Named molecular identity | Does the sequence, form and analytical assignment match this product? |
| Nominal amount versus content | Is the quantity only a label declaration or also supported by a calibrated content assay? |
| Purity | Which separation method and reporting basis were used? |
| Product/lot traceability | Does the report match the supplied material, lot and presentation? |
| Finished format | Is cartridge condition, container compatibility or performance separately documented where claimed? |
You may ask for documentation before ordering using Batch Documentation. Include the exact name TB-500 Refill 10mg, state that your enquiry is before purchase and describe what your laboratory needs. After delivery, include the container lot and order number. A report for another lot or product format must not be substituted for the record of the item supplied.
The CoA-reading guide, HPLC interpretation guide, and mass-spectrometry guide explain the limits of the individual methods. The existence of these guides is not evidence that every particular test was performed for this product.
Storage, dispatch and receiving
Use the actual product label and lot-applicable documented conditions for unopened storage, transit excursions and any laboratory preparation. The material reviewed does not establish a universal temperature, fixed expiry, freeze-thaw allowance or solution stability interval for this particular product.
A sealed refill cartridge is not automatically equivalent to a vial. Check the supplied container and closure on receipt. Compatibility with a pen housing, adapter or existing hardware must be verified for the exact product; no universal interchangeability is established by the word refill.
At delivery, compare the item name, nominal amount, packaging and lot with the order. Record any mismatch before using the material. The receiving-inspection checklist, storage-temperature guide, vial/pen comparison and warm/delayed-delivery guide provide the corresponding supporting checks.
Core Research publishes dispatch from Birmingham, United Kingdom, and plain outer packaging. Actual delivery charges and estimates vary by order and destination: consult Shipping & Delivery and the checkout’s available options. No unconditional next-day service is promised here.
Frequently asked product questions
Does this refill include a complete reusable pen?
This is a separately listed refill cartridge, not a promise that a complete reusable device body or accessories are included. Check the exact inclusions and compatibility with Core Research before buying.
Is it compatible with any peptide pen?
No universal compatibility is established. Verify the relevant housing/cartridge system and the supplier’s exact specification; matching molecule names do not demonstrate compatible hardware.
Is TB-500 the same as full-length thymosin beta-4?
Not necessarily. Published materials called TB-500 include short fragments; the exact material in this item needs a matching molecular specification. Evidence for a parent protein or one fragment is not automatically evidence for another.
Can I get the batch report before purchasing?
You can submit a pre-purchase documentation enquiry by naming this exact product and the information needed. Confirm which lot/presentation the available report covers; the request route does not guarantee that every type of test has been completed.
What happens if the shipment arrives damaged or unusually warm?
Retain the parcel and order details, photograph the condition before using the material, and contact Core Research promptly with tracking and available lot information. Use the arrival-condition guide to document the concern.
Ordering and support
The live product purchase panel is the source for current price, stock status, quantity and basket action. If your decision requires a confirmed specification, included components, available testing report or compatible device, contact Core Research product support first with the exact product title. Use Batch Documentation for pre-purchase or received-lot records. The quality-testing methodology, delivery terms and research-use policy give the relevant service context.
For laboratory research only; not for human or veterinary use. Experimental cell, animal and early human observations are not a personal-use or therapeutic protocol for this supplied item.
Selected research references
[1] Esposito et al. (2012). Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis.
[2] Van Troys et al. (1996). The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO Journal.
[3] Philp et al. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration.
[4] Shah et al. (2018). Thymosin β4 inhibits PDGF-BB induced activation, proliferation, and migration of human hepatic stellate cells via its actin-binding domain. Expert Opinion on Therapeutic Targets.
[5] Rahaman et al. (2024). Simultaneous quantification of TB-500 and its metabolites and screening by wound-healing activities in vitro. Journal of Chromatography B.




